<DOC>
	<DOC>NCT01724385</DOC>
	<brief_summary>To evaluate the efficacy of intravitreal bevacizumab injections for treatment of proliferative diabetic retinopathy (PDR) with new dense vitreous hemorrhage (VH) after previous full panretinal photocoagulation (PRP).</brief_summary>
	<brief_title>Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy</brief_title>
	<detailed_description>The investigators will carry out a prospective study in patients with PDR and prior complete laser treatment who presented with new dense VH. All eyes will be treated with intravitreal injection of bevacizumab (1.25 mg). Complete ophthalmic examination and/or ocular ultrasonography will be performed at baseline and 1, 6, 12 weeks and 6, 9, 12 months after first injection. Re-injection will be done in non-clearing and recurrent VH.</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Vitreous Hemorrhage</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>patients with diabetes mellitus proliferative diabetic retinopathy prior complete panretinal photocoagulation presented with new dense vitreous hemorrhage oneeyed patient previous intraocular surgery severe lens opacity precluding fundus examination advance glaucoma history of thromboembolic events such as myocardial infarction and cerebrovascular accident uncontrolled systemic hypertension, systolic blood pressure &gt; 180 mmHg or diastolic blood pressure &gt; 110 mmHg known coagulation abnormalities or current use of anticoagulant medications other than aspirin known allergies to any relevant drugs in this study evidence of external ocular infection such as conjunctivitis and significant blepharitis.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>bevacizumab,</keyword>
	<keyword>proliferative diabetic retinopathy,</keyword>
	<keyword>vitreous hemorrhage,</keyword>
</DOC>